Show simple item record

dc.creatorSenćanski, Milan V.
dc.creatorRadosevic, Draginja
dc.creatorPerović, Vladimir R.
dc.creatorGemović, Branislava S.
dc.creatorStanojevic, Maja
dc.creatorVeljković, Nevena V.
dc.creatorGlišić, Sanja
dc.date.accessioned2018-03-01T16:30:35Z
dc.date.available2018-03-01T16:30:35Z
dc.date.issued2015
dc.identifier.issn1381-6128 (print)
dc.identifier.issn1873-4286 (electronic)
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/806
dc.description.abstractThe influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.en
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173001/RS//
dc.rightsrestrictedAccessen
dc.sourceCurrent Pharmaceutical Designen
dc.subjectInfluenza diseaseen
dc.subjectnatural compoundsen
dc.subjecttherapeutic targetsen
dc.subjectdrug developmenten
dc.subjectdrug repurposingen
dc.subjectinfluenza hemagglutinin inhibitorsen
dc.subjectinfluenza NS1 inhibitorsen
dc.subjectinfluenza polymerase inhibitorsen
dc.titleNatural Products as Promising Therapeutics for Treatment of Influenza Diseaseen
dc.typearticleen
dcterms.abstractРадосевиц, Драгиња; Сенчански Милан В.; Перовић Владимир; Гемовић Бранислава; Вељковић Невена В.; Глишић Сања; Станојевиц, Маја;
dc.citation.volume21
dc.citation.issue38
dc.citation.spage5573
dc.citation.epage5588
dc.identifier.wos000364518900009
dc.identifier.doi10.2174/1381612821666151002113426
dc.citation.rankM21
dc.identifier.pmid26429712
dc.identifier.scopus2-s2.0-84957056707


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record